Telmisartan Patent for Canine Hypertension Treatment
Summary
USPTO granted Patent US12605366B2 to inventors Anne Michelle Traas, Amanda Erickson Coleman, Bianca Natália Ferreira De Moura Lourenco, Kate Elizabeth Creevy, and Scott Alan Brown for telmisartan use in treating hypertension in dogs. The patent covers administration of telmisartan in variable daily dosages over a treatment period. Patent holders gain enforceable exclusivity rights.
What changed
USPTO granted Patent US12605366B2 covering telmisartan or a pharmaceutically acceptable salt thereof as a medicament for treating hypertension in dogs, with a daily dosage amount varied over a treatment period. The patent grants the inventors enforceable exclusivity over this specific veterinary application of the compound.
Affected parties include pharmaceutical companies and veterinary drug manufacturers with interests in telmisartan formulations for animal health. No third-party compliance obligations are created by this grant. Parties seeking to develop or commercialize similar canine hypertension treatments should review this patent for potential licensing needs or freedom-to-operate considerations.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Telmisartan for the treatment of hypertension in dogs
Grant US12605366B2 Kind: B2 Apr 21, 2026
Inventors
Anne Michelle Traas, Amanda Erickson Coleman, Bianca Natália Ferreira De Moura Lourenco, Kate Elizabeth Creevy, Scott Alan Brown
Abstract
The present invention relates to telmisartan or a pharmaceutically acceptable salt thereof as a medicament for the treatment of hypertension in dogs, wherein the therapeutically effective amount of telmisartan is administered in a daily dosage amount that is varied over a treatment period.
CPC Classifications
A61K 31/401 A61K 31/4184 A61P 9/12
Filing Date
2020-04-30
Application No.
17596356
Claims
15
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.